Démaris, A.; Widigson, E.S.K.; Ilvemark, J.F.K.F.; Steenholdt, C.; Seidelin, J.B.; Huisinga, W.; Michelet, R.; Aulin, L.B.S.; Kloft, C.
Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics 2022, 14, 2095.
https://doi.org/10.3390/pharmaceutics14102095
AMA Style
Démaris A, Widigson ESK, Ilvemark JFKF, Steenholdt C, Seidelin JB, Huisinga W, Michelet R, Aulin LBS, Kloft C.
Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics. 2022; 14(10):2095.
https://doi.org/10.3390/pharmaceutics14102095
Chicago/Turabian Style
Démaris, Alix, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, and Charlotte Kloft.
2022. "Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review" Pharmaceutics 14, no. 10: 2095.
https://doi.org/10.3390/pharmaceutics14102095
APA Style
Démaris, A., Widigson, E. S. K., Ilvemark, J. F. K. F., Steenholdt, C., Seidelin, J. B., Huisinga, W., Michelet, R., Aulin, L. B. S., & Kloft, C.
(2022). Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review. Pharmaceutics, 14(10), 2095.
https://doi.org/10.3390/pharmaceutics14102095